85953-39-5

Usage

Type of compound

Sulfonyl chloride derivative of indole

Usage

Reactant in organic synthesis for the preparation of various indole derivatives

Reactivity

Known for its ability to undergo nucleophilic substitution reactions

Application

Utilized in the pharmaceutical industry for the synthesis of biologically active compounds

Importance

Plays a crucial role in the development of new drugs and in the study of indole chemistry

Upstream product

• 40899-71-6 1-benzenesulfonylindole 
• 4111-54-0 lithium diisopropyl amide 
• 3770-50-1 2-carbethoxyindole 
• 100-63-0 phenylhydrazine 
• 1394431-02-7 lithium 1-(phenylsulfonyl)-1H-indole-2-sulfinate 
• 98-09-9 benzenesulfonyl chloride 
• 120-72-9 indole 

Downstream Products

• 85953-40-8 1-(phenylsulfonyl)indole-2-sulfonamide 
• 1394431-03-8 N-(4-methoxybenzyl)-1-(phenylsulfonyl)-1H-indole-2-sulfonamide 
• 1394431-04-9 N-(4-methoxybenzyl)-1H-indole-2-sulfonamide 
• 1394431-52-7 N-(4-bromobenzyl)-1H-indole-2-sulfonamide 
• 1394431-06-1 N-(biphenyl-4-ylmethyl)-1H-indole-2-sulfonamide 
• 1394431-13-0 N-((4'-fluorobiphenyl-4-yl)methyl)-1H-indole-2-sulfonamide 
• 1394431-15-2 N-((4'-methoxybiphenyl-4-yl)methyl)-1H-indole-2-sulfonamide 
• 1394431-25-4 N-((4'-(dimethylamino)biphenyl-4-yl)methyl)-1H-indole-2-sulfonamide 
• 1394431-30-1 N-(1-(4'-methylbiphenyl-4-yl)methyl)-1H-indole-2-sulfonamide 
• 1394431-67-4 N-((4'-hydroxy-3'-methoxybiphenyl-4-yl)methyl)-1H-indole-2-sulfonamide 
• 1394431-55-0 N-((4'-fluorobiphenyl-3-yl)methyl)-1-(phenylsulfonyl)-1H-indole-2-sulfonamide 
• 1394431-56-1 N-((4'-fluorobiphenyl-3-yl)methyl)-1H-indole-2-sulfonamide 
• 1394431-46-9 N-(4-(6-ethoxypyridin-3-yl)benzyl)-1H-indole-2-sulfonamide 
• 1394431-11-8 N-(4-bromobenzyl)-1-(phenylsulfonyl)-1H-indole-2-sulfonamide 

Relevant academic research and scientific papers

Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators

Existing CB1 negative allosteric modulators (NAMs) fall into a limited range of structural classes. In spite of the theoretical potential of CB1 NAMs, published in vivo studies have generally not been able to demonstrate the expected therapeutically-relevant CB1-mediated effects. Thus, a greater range of molecular tools are required to allow definitive elucidation of the effects of CB1 allosteric modulation. In this study, we show a novel series of indole sulfonamides. Compounds 5e and 6c (ABD1075) had potencies of 4 and 3?nM respectively, and showed good oral exposure and CNS penetration, making them highly versatile tools for investigating the therapeutic potential of allosteric modulation of the cannabinoid system.

N- (ARYLALKYL) - 1H- INDOLE- 2 - SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain /V-(arylalkyl)-1 H-indole- 2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

Hydantoin derivatives

The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives. The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.

Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides

Derivatives of benzofuran- and indole-2-sulfonamide were prepared for evaluation as topically active ocular hypotensive agents. These compounds were found to be excellent inhibitors of carbonic anhydrase and to lower intraocular pressure in a rabbit model

Herbicidal indole sulfonamides

This invention relates to novel N-(heterocyclicaminocarbonyl) indole sulfonamides which are useful as agricultural chemicals and, in particular, as herbicides.